BRISTOL-MYERS SQUIBB COMPANY Treasury Stock, Value
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Treasury Stock, Value of $43.67 billion as of 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Treasury Stock, Value
us-gaap:TreasuryStockValue · last filed 2024-10-31
- 2024-09-30: Treasury Stock, Value $43.67B.
- 2024-06-30: Treasury Stock, Value $43.69B.
- 2024-03-31: Treasury Stock, Value $43.70B.
- 2023-12-31: Treasury Stock, Value $43.77B.
| Period end | Treasury Stock, Value |
|---|---|
| 2024-09-30 | $43.67B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $43.69B 10-Q · filed 2024-07-26 |
| 2024-03-31 | $43.70B 10-Q · filed 2024-04-25 |
| 2023-12-31 | $43.77B 10-Q · filed 2024-10-31 |
| 2023-09-30 | $43.08B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $39.68B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $38.81B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $38.62B 10-Q · filed 2023-10-26 |
| 2022-09-30 | $36.41B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $35.29B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $35.19B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $31.26B 10-Q · filed 2022-10-26 |
| 2021-09-30 | $28.57B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $28.20B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $27.20B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $26.24B 10-K · filed 2022-02-09 |
| 2020-09-30 | $25.28B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $25.65B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $24.76B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $25.36B 10-K · filed 2021-02-10 |
| 2019-09-30 | $19.87B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $19.57B 10-Q · filed 2019-07-25 |
| 2019-03-31 | $19.57B 10-Q · filed 2019-04-25 |
| 2018-12-31 | $19.57B 10-K · filed 2020-02-24 |
| 2018-09-30 | $19.58B 10-Q · filed 2018-10-25 |
| 2018-06-30 | $19.58B 10-Q · filed 2018-07-26 |
| 2018-03-31 | $19.43B 10-Q · filed 2018-04-26 |
| 2017-12-31 | $19.25B 10-K · filed 2019-02-25 |
| 2017-09-30 | $19.00B 10-Q · filed 2017-10-26 |
| 2017-06-30 | $18.78B 10-Q · filed 2017-07-27 |
| 2017-03-31 | $18.39B 10-Q · filed 2017-04-27 |
| 2016-12-31 | $16.78B 10-K · filed 2018-02-13 |
| 2016-09-30 | $16.80B 10-Q · filed 2016-10-27 |
| 2016-06-30 | $16.80B 10-Q · filed 2016-07-28 |
| 2016-03-31 | $16.82B 10-Q · filed 2016-04-28 |
| 2015-12-31 | $16.56B 10-K · filed 2017-02-21 |
| 2015-09-30 | $16.61B 10-Q · filed 2015-10-27 |
| 2015-06-30 | $16.65B 10-Q · filed 2015-07-23 |
| 2015-03-31 | $16.68B 10-Q · filed 2015-04-28 |
| 2014-12-31 | $16.99B 10-K · filed 2016-02-12 |
| 2014-09-30 | $17.12B 10-Q · filed 2014-10-24 |
| 2014-06-30 | $17.17B 10-Q · filed 2014-07-24 |
| 2014-03-31 | $17.22B 10-Q · filed 2014-04-29 |
| 2013-12-31 | $17.80B 10-K · filed 2015-02-13 |
| 2013-09-30 | $17.98B 10-Q · filed 2014-10-24 |
| 2013-06-30 | $18.02B 10-Q · filed 2014-07-24 |
| 2013-03-31 | $18.32B 10-Q · filed 2014-04-29 |
| 2012-12-31 | $18.82B 10-Q · filed 2014-10-24 |
| 2012-09-30 | $18.48B 10-Q · filed 2013-10-23 |
| 2012-06-30 | $17.60B 10-Q · filed 2013-07-25 |
| 2012-03-31 | $17.29B 10-Q · filed 2013-04-25 |
| 2011-12-31 | $17.40B 10-K · filed 2014-02-14 |
| 2011-09-30 | $17.39B 10-Q · filed 2012-10-24 |
| 2011-06-30 | $17.19B 10-Q · filed 2012-07-25 |
| 2011-03-31 | $17.30B 10-Q · filed 2012-04-26 |
| 2010-12-31 | $17.45B 10-K · filed 2014-02-14 |
| 2010-09-30 | $17.30B 10-Q · filed 2011-10-27 |
| 2010-06-30 | $17.27B 10-Q · filed 2011-07-28 |
| 2010-03-31 | $17.17B 10-Q · filed 2011-04-28 |
| 2009-12-31 | $17.36B 10-K · filed 2012-02-17 |
| 2009-09-30 | $10.50B 10-Q · filed 2010-10-26 |
| 2009-06-30 | $10.51B 10-Q · filed 2009-07-23 |
| 2008-12-31 | $10.57B 10-K · filed 2012-02-17 |
| 2007-12-31 | $10.58B 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |